HPV Vaccine as a Cervical Cancer Prevention Strategy in Indonesia
Article Sidebar
Main Article Content
Abstract
Cervical cancer is the third most common cancer in women in the world and the second most common in women in Indonesia. Cervical cancer accounts for 7.5% of cancer deaths in the world and most of them come from developing countries including Indonesia. The cause of cervical cancer is high-risk HPV and can actually be prevented through high-risk HPV vaccines that are available throughout the world, including Indonesia.
Discussion: The HPV vaccine has been shown to be effective in preventing cervical cancer, which is known to reduce the incidence by up to 90%. Various preparations of the HPV vaccine have been shown to be safe to give to patients. Conditions in Indonesia currently make the HPV vaccine a mandatory vaccine given as part of the school children's immunization month program as an effort to prevent cervical cancer for the community in the future.
Conclusion: The HPV vaccine has effectiveness and side effects that are safe to be given to the public at large. The policy in Indonesia to require the provision of the HPV vaccine in the schoolchildren's immunization month program is the right step to prevent cervical cancer.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
References
2. Beban kanker di Indonesia. Pusat Data dan Informasi Kementerian Kesehatan RI. 2019.
3. World Health Organization, Regional Office for South-East Asia. Strategic Framework for the Comprehensive Control of Cancer Cervix in South-East Asia Region. New Delhi: WHO; 2015.
4. Sankaranarayanan R. HPV vaccination: The most pragmatic cervical cancer primary prevention strategy. Int J Gynaecol Obstet. 2015;131:33–5.
5. Saraiya M, Unger ER, Thompson TD, Lynch CF, Hernandez BY, Lyu CW, et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst. 2015;107:djv086.
6. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec. 2014;89:465–91.
7. Hoffman BL, Schorge JO, Bradshaw KD, Halvorson LM, Schaffer JI, Corton MM. Williams gynecology. 3rd ed. New York: McGraw-Hill Medical; 2016. P.737-8
8. World Health Organization. GACVS Safety Update on HPV Vaccines, Geneva 17 December. WHO. 2013.
9. World Health Organization. Global Advisory Committee on Vaccine Safety, Statement on the Continued Safety of HPV Vaccination. Geneva: WHO; 2014.
10. World Health Organization. Global Advisory Committee on Vaccine Safety, Statement on Safety of HPV Vaccines: 17 December, 2015. Geneva: WHO; 2015.
11. Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30(Suppl 5):F123–38.
12. Meites E, Szilagyi PG, Chesson HW, et al. Human papillomavirus vaccination for adults: Updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morbidity and Mortality Weekly Report 2019; 68(32):698–702.
13. Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination — Updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morbidity and Mortality Weekly Report 2016; 65:1405–1408.
14. Kementerian Kesehatan Republik Indonesia. Riset Kesehatan Dasar 2018. 2018.
15. Kusuma F, Suryoadji KA, Adrian M, et al. Socio-demographic Profiles of Cervical Cancer Patients at Cipto Mangunkusumo Hospital - 2009-2019 and Its Association with Cancer Stages at Diagnosis. CDK. 2022;49(5):245-7.
16. Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia. Jadwal imunisasi dewasa: rekomendasi satgas imunisasi dewasa PAPDI tahun 2017. PAPDI. 2017.
17. Kementerian Kesehatan Republik Indonesia. Kemenkes Tambah 3 Jenis Vaksin Imunisasi Rutin, Salah Satunya HPV. KEMENKES RI. 2022.